List view / Grid view
An assay is an analytical procedure in laboratory medicine, pharmacology and molecular biology for measuring the activity of a target entity.
DNA in the cytoplasm is an indicator of microbial infection, serving as a danger signal and resulting in induction of an innate immune response via the cyclic GAMP synthase (cGAS)/STING (Stimulator of INterferon-sensitive Genes) pathway.
Included in this In-Depth Focus are articles on why human tissue models are best for testing nephrotoxicity and how genetic and pharmacogenomic testing can improve healthcare options.
Drug Target Review has created a COVID-19 research hub with forum space for discussions and a place to share your research - plus all of our articles and news.
This issue includes a spotlight on how genomic assays could revolutionise healthcare, a discussion on how lab automation can improve drug discovery and an analysis of whether antibodies can provide an effective coronavirus treatment. Other article topics in this issue include immuno-oncology and artificial intelligence.
Multiple co-signalling molecules regulate T cell activation.
Researchers have developed a novel affordable and reproducible assay to study the malaria parasite, using a new cytoplasmic dye, Cell Trace Far-Red (CTFR).
A new microfluidic technology has been developed by researchers, which utilises magnetic ferrobots to automate chemical analyses and assays.
25 February 2020 | By Bruker Daltonics
Learn about the latest software tools for Bruker Daltonic’s SPR instrumentation and explore high-throughput screening strategies enabled by their ecosystem.
Read how Cyto-Mine® has helped improve overall efficiency and productivity in cell line development at FUJIFILM Diosynth Biotechnologies.
Hybridoma-based antibody discovery: the challenges and how to overcome them using microfluidic picodroplet technology.
In vitro evaluation of hepatic function using a primary human hepatocyte 3D spheroid culture system
Hypoxia measurements in live and fixed cells using fluorescence microscopy and high-content imaging
Enzyme Linked Immunosorbent Assays (ELISAs) are one of the most common immunoassays on the market.
It is said that, on average, it takes a new drug 12 years to go from research lab to patient, with many thousands of candidates discarded along the way. Can artificial intelligence (AI) help to speed things up? Sheraz Gul and Alp Sahin provide an overview of an AI approach…
Researchers have developed a luciferase assay that can be used to monitor the effects of treatments on six different molecular targets at once.
